ESMO: Daiichi's HER3-Targeting ADC Shows Promise, Particularly In Resistant Tumors

Potential First-In-Class Agent

 
• By John Davis
  
Arrows
Targeting HER3 May Be A Winning Strategy • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D